# Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer

> **NCT00300950** · PHASE2 · COMPLETED · sponsor: **GlobeImmune** · enrollment: 176 (actual)

## Conditions studied

- Pancreas Cancer

## Interventions

- **BIOLOGICAL:** GI-4000
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00300950
- **Lead sponsor:** GlobeImmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2015-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00300950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00300950, "Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00300950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*